Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) saw its stock price increase by 12% over the past week. This movement could be associated with several recent developments. The company announced a ...

Recursion has stumbled through an early test of its tech-enabled drug discovery, reporting a hit on safety but failing to wow on the efficacy front.

Recursion Pharmaceuticals (NasdaqGS:RXRX) has demonstrated resilience amid recent financial challenges, with the stock experiencing a 34% increase over the last month. This notable price movement ...

Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per ...

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...

Recursion Pharmaceuticals said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding crunch and the current policy uncertainty.

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy ...